Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 2, 2004, Pages 127-133

  Schnur, János ^a   Oláh, Julia ^a   Szepesi, Ágota ^a   Nagy, Péter ^a   Thorgeirsson, Snorri S ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cirrhosis; Fibrosis; Liver; MMP 2; MMP 9; TGF 1; Thioacetamide

Indexed keywords

GELATIN; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN; GELATINASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; ARTICLE; FIBROSIS; HYBRIDIZATION; LIVER; LIVER FIBROSIS; MORPHOMETRICS; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; TISSUE SECTION; TRANSGENIC MOUSE; WILD TYPE; ZYMOGRAPHY; ANIMAL; EXPERIMENTAL LIVER CIRRHOSIS; FEMALE; MALE; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY;

ANIMALS; BLOTTING, NORTHERN; COLLAGEN; FEMALE; GELATINASES; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; RNA, MESSENGER; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 2642527018     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200402000-00002     Document Type: Article

References (23)

1. Nagy P, Schaff ZS, Lapis K. Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases. Hepatology 1991; 14:269-273.
2. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alpha therapy. N Engl J Med 1991; 324:933-940.
3. Gressner AM, Weiskirchen R, Breitkopf K, Doolay S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7;d793-807.
4. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000; 32:247-255.
5. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92:2572-2576.
6. Kopp JB, Vactor VM, Mozes M, Nagy P, Sanderson N, Bötinger EP, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74:991-1003.
7. Müller D, Enderle GJ, Low O, Dietze E, Krell H. Bile ductular proliferation and altered leukotriene elimination in thioacetamide-induced fibrosis of rat liver. J Hepatol 1996; 25:547-553.
8. Bissell DM. Sex and hepatic fibrosis. Hepatology 1999; 29:988-989.
9. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993; 328:1828-1835.
10. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261:4337-4345.
11. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-1904.
12. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol 1986; 103:2403-2410.
13. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5:2145-2154.
14. Timár F, Botyánszki J, Süli-Vargha H, Babó I, Oláh J, Pogány G, et al. The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site. Cancer Chemother Pharmacol 1998; 41:292-298.
15. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999; 29:719-727.
16. Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995; 21:787-795.
17. Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144:528-537.
18. Lichtinghagen R, Breitenstein K, Arndt B, Kühbacher T, Böker KH. Comparison of matrix metalloproteinase expression in normal and cirrhotic human liver. Virchows Arch 1998; 432:153-158.
19. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998; 153:1895-1902.
20. Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999; 29:1730-1738.
21. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46: 443-446.
22. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res 1990; 122:77-85.
23. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31:828-833.